Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Edema 2Brain Neoplasms 2Brain Edema 2Astrocytoma 2

Interventions

Cyclophosphamide 1499Cisplatin 1436Paclitaxel 1342Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1135Bevacizumab 1071Fluorouracil 907Doxorubicin 805Dexamethasone 755Rituximab 745Capecitabine 736Oxaliplatin 710pembrolizumab 700Etoposide 679Irinotecan 641Filgrastim 624Nivolumab 588Cytarabine 587Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 437

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Corticotropin-Releasing Hormone × Clear all
NCT00088166 2014-08-13

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Celtic Pharma Development Services

Phase 3 Completed
200 enrolled 17 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

NCT00226655 2012-08-31

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Celtic Pharma Development Services

Phase 3 Completed
112 enrolled 8 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡